vs
Side-by-side financial comparison of HeartCore Enterprises, Inc. (HTCR) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
HeartCore Enterprises, Inc. is the larger business by last-quarter revenue ($3.0M vs $2.2M, roughly 1.3× Instil Bio, Inc.). HeartCore Enterprises, Inc. runs the higher net margin — 14.5% vs -365.3%, a 379.9% gap on every dollar of revenue. On growth, Instil Bio, Inc. posted the faster year-over-year revenue change (-19.2% vs -81.6%).
HeartCore Enterprises, Inc. is a global SaaS provider specializing in customer experience management, digital transformation solutions, and marketing technology tools. It operates mainly in Japan, Asia-Pacific, and North America, serving small-to-medium businesses and large enterprises with content management systems, marketing automation platforms, and CRM solutions.
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
HTCR vs TIL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0M | $2.2M |
| Net Profit | $434.1K | $-8.2M |
| Gross Margin | 49.1% | — |
| Operating Margin | -0.4% | -426.3% |
| Net Margin | 14.5% | -365.3% |
| Revenue YoY | -81.6% | -19.2% |
| Net Profit YoY | -96.1% | 31.1% |
| EPS (diluted) | $0.02 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.2M | ||
| Q3 25 | $3.0M | $2.2M | ||
| Q2 25 | $4.7M | $2.2M | ||
| Q1 25 | $3.6M | $2.2M | ||
| Q4 24 | $-2.7M | $2.8M | ||
| Q3 24 | $16.2M | $1.5M | ||
| Q2 24 | $4.1M | $0 | ||
| Q1 24 | $5.0M | $0 |
| Q4 25 | — | $-8.2M | ||
| Q3 25 | $434.1K | $-13.6M | ||
| Q2 25 | $1.1M | $-21.4M | ||
| Q1 25 | $-3.1M | $-28.2M | ||
| Q4 24 | $-9.3M | $-11.9M | ||
| Q3 24 | $11.1M | $-23.0M | ||
| Q2 24 | $-2.0M | $-14.9M | ||
| Q1 24 | $-1.3M | $-24.3M |
| Q4 25 | — | — | ||
| Q3 25 | 49.1% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 86.3% | — | ||
| Q2 24 | 19.8% | — | ||
| Q1 24 | 40.3% | — |
| Q4 25 | — | -426.3% | ||
| Q3 25 | -0.4% | -670.0% | ||
| Q2 25 | 2.3% | -1045.5% | ||
| Q1 25 | -34.7% | -1363.2% | ||
| Q4 24 | 386.5% | -426.1% | ||
| Q3 24 | 76.0% | -1582.8% | ||
| Q2 24 | -37.1% | — | ||
| Q1 24 | -13.5% | — |
| Q4 25 | — | -365.3% | ||
| Q3 25 | 14.5% | -606.0% | ||
| Q2 25 | 23.2% | -954.2% | ||
| Q1 25 | -86.1% | -1257.8% | ||
| Q4 24 | 346.8% | -428.8% | ||
| Q3 24 | 68.1% | -1541.9% | ||
| Q2 24 | -48.0% | — | ||
| Q1 24 | -26.4% | — |
| Q4 25 | — | $-1.13 | ||
| Q3 25 | $0.02 | $-2.01 | ||
| Q2 25 | $0.04 | $-3.24 | ||
| Q1 25 | $-0.14 | $-4.32 | ||
| Q4 24 | $-0.45 | $-1.82 | ||
| Q3 24 | $0.53 | $-3.54 | ||
| Q2 24 | $-0.09 | $-2.29 | ||
| Q1 24 | $-0.06 | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $6.6M |
| Total DebtLower is stronger | $510.9K | — |
| Stockholders' EquityBook value | $5.2M | $113.9M |
| Total Assets | $13.3M | $203.5M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.6M | ||
| Q3 25 | $4.4M | $5.8M | ||
| Q2 25 | $2.5M | $7.7M | ||
| Q1 25 | $2.3M | $15.4M | ||
| Q4 24 | $6.5M | $8.8M | ||
| Q3 24 | $8.6M | $6.7M | ||
| Q2 24 | $4.2M | $6.8M | ||
| Q1 24 | $1.6M | $5.5M |
| Q4 25 | — | — | ||
| Q3 25 | $510.9K | — | ||
| Q2 25 | $1.5M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $545.1K | — | ||
| Q3 24 | $1.9M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | — | $113.9M | ||
| Q3 25 | $5.2M | $120.4M | ||
| Q2 25 | $4.8M | $131.7M | ||
| Q1 25 | $1.8M | $144.9M | ||
| Q4 24 | $4.7M | $169.4M | ||
| Q3 24 | $12.4M | $176.3M | ||
| Q2 24 | $1.6M | $195.0M | ||
| Q1 24 | $3.9M | $205.8M |
| Q4 25 | — | $203.5M | ||
| Q3 25 | $13.3M | $211.8M | ||
| Q2 25 | $13.5M | $231.0M | ||
| Q1 25 | $10.2M | $237.4M | ||
| Q4 24 | $14.0M | $263.6M | ||
| Q3 24 | $25.5M | $272.6M | ||
| Q2 24 | $24.1M | $294.3M | ||
| Q1 24 | $22.3M | $306.3M |
| Q4 25 | — | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | $-674.1K | $-14.8M | ||
| Q1 25 | $-2.0M | $-4.2M | ||
| Q4 24 | $-1.3M | $-10.6M | ||
| Q3 24 | $-1.8M | $-20.1M | ||
| Q2 24 | $-837.1K | $-10.6M | ||
| Q1 24 | $-898.6K | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTCR
| Customised Software Development And Services | $1.7M | 58% |
| Software Related Cost Of Revenues | $1.4M | 46% |
TIL
Segment breakdown not available.
